Calytrix Bio develops treatments for various blood disorders, mainly essential thrombocythemia and myelofibrosis.
Eli Lilly, which makes the weight-loss drug Zepbound, is a major competitor of Denmark’s Novo Nordisk.
Calytrix Bio was founded in 2025 by JP Morgan Life Sciences Private Capital.








What do you think?